News

The open-label, dose escalation study is designed to define the recommended dose of XmAb2513 for subsequent trials, to determine its safety and tolerability, characterize pharmacokinetics and immunogenicity, and

The closing is expected to take place on or about February 13, 2008, subject to the satisfaction of customary closing conditions.

The study will be conducted using an eFlow Electronic Nebulizer optimized for delivery of Kamada’s Alpha-1 Antitrypsin (AAT) product. Kamada’s inhaled AAT has been designated an orphan drug

Twenty-four healthy postmenopausal women have been enrolled in the study, which will measure the effect of the drug on a well-established biochemical marker. The dosing is scheduled to

According to one of the market reports, the pharmaceutical industry is said to employ varied marketing tactics to entice nurse-prescribers to influence choices made by medics and other

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor and is currently in one Phase I combination clinical trial with Taxotere for solid tumors, two Phase I/II combination trials with

According to Gail Cassell, vice president for scientific affairs at Eli Lilly, FDA is steeped in a plethora of inadequacies like dearth of scientists who understand new technologies,

According to the company, the Sandman Intro CPAP device is a convenient device designed for a broad range of patients and provides continuous positive airway pressure and heated

The study compared pixantrone with the related drug, mitoxantrone, an agent currently approved to treat severe multiple sclerosis, also an autoimmune disease that attacks the central nervous system.